Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Short Communication Volume 8 Issue 6

Precision Diabetes - Genes Lead the Way!

Dr. Anusha Sunder*

Doctorate in Lifescience/Human Nutrition, Accredited Certification in Nutrigenetics, Lead Scientist and Nutrigenetic Expert, Xcode Life Sciences, Pvt. Ltd. Chennai, India

*Corresponding Author: Dr. Anusha Sunder, Doctorate in Lifescience/Human Nutrition, Accredited Certification in Nutrigenetics, Lead Scientist and Nutrigenetic Expert, Xcode Life Sciences, Pvt. Ltd. Chennai, India.

Received: May 09, 2024; Published: May 21, 2024

Abstract

Diabetes, the sugary health challenge, is growing fast in 21st century by almost tripling its count over the past 20 years [1,2]. Diagnosis, monitoring and therapy of several diseases, including diabetes, have transitioned to individualized models of care shifting away from typical ‘one size fits all’ approach. Consequently, precision medicine grabs limelight globally, with a promising role in diabetes care [3,4].

References

  1. International Diabetes Federation (IDF); Diabetes Atlas, 9th Edition, (2019).
  2. International Diabetes Federation (IDF); Diabetes Atlas, 9th Worldwide toll of Diabetes (2019).
  3. Viswanathan Mohan and Ranjit Unnikrishnan. “Precision diabetes: Where do we stand today?” Indian Journal of Medical Research5 (2018): 472-475.
  4. Ragia G., et al. “Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas”. Pharmacogenomics11 (2009): 1781-1787.
  5. Chung WK., et al. “Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)”. Diabetologia 9 (2020): 1671-1693.
  6. Pearson ER., et al. “Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study”. Diabetes 56 (2007): 2178-2182.
  7. Holstein A., et al. “TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes”. BMC Medical Genetics 12 (2011): 30.
  8. Schroner Z., et al. “Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes”. Diabetes, Obesity and Metabolism1 (2011): 89-91.
  9. Javorský M., et al. “Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide”. International Journal of Endocrinology 2013 (2013):
  10. Kang ES., et al. “Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes”. Clinical Pharmacology Therapy 2 (2005): 202-208.
  11. Hsieh MC., et al. “Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus”. Metabolism8 (2010): 1139-1144.
  12. Zhou K., et al. “Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study”. Clinical Pharmacology Therapy1 (2010): 52-56.
  13. Dawed AY., et al. “CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes”. Diabetes Care11 (2016): 1902-1908.
  14. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K., et al. “Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes”. Nature Genetics2 (2011): 117-120.
  15. Zhou K., et al. “Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin”. Nature Genetics9 (2016): 1055-1059.
  16. Dujic T., et al. “Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: A GoDARTS study”. Diabetes Care 39 (2016): 1896-1901.
  17. Ragia G., et al. “Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas”. Pharmacogenomics 10 (2009): 1781-1787.
  18. Lemelman MB., et al. “Neonatal Diabetes Mellitus: An Update on Diagnosis and Management”. Clinical Perinatology 1 (2018): 41-59.

Citation

Citation: Dr. Anusha Sunder. “Precision Diabetes - Genes Lead the Way!”.Acta Scientific Medical Sciences 8.6 (2024): 76-78.

Copyright

Copyright: © 2024 Dr. Anusha Sunder. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US